Observational study on conditions for access to the analysis of KRAS mutation in patients with metastatic colorectal cancer receiving panitumumab treatment;Étude observationnelle sur les conditions d'accès à l'analyse de la mutation du gène KRAS chez les patients atteints de cancer colorectal métastatique recevant un traitement par panitumumab

Bulletin du Cancer

Volumn 99, Issue 7-8, 2012, Pages 743-751

  Bibeau, Frédéric ^a   Louvet, Christophe ^b   Afchain, Pauline ^c   Mitry, Emmanuel ^d,e   Artru, Pascal ^f   André, Thierry ^c,g  

^a CENTRE VAL D AURELLE   (France)

^b INSTITUT MUTUALISTE MONTSOURIS   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d INSTITUT CURIE   (France)

^e LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^f Centre Orthopédique Santy Hôpital Privé Jean Mermoz   (France)

^g SORBONNE UNIVERSITÉ   (France)

Author keywords

Anti EGFR antibodies; Colorectal cancer; Genotyping; KRAS; Panitumumab

Indexed keywords

K RAS PROTEIN; PANITUMUMAB; TUMOR MARKER;

ARTICLE; COLORECTAL CANCER; DESCRIPTIVE RESEARCH; FRANCE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIMARY TUMOR; RETROSPECTIVE STUDY;

EID: 84863887211     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2012.1612     Document Type: Article

References (31)

1. Guérin S, Hill C. Cancer epidemiology in France in 2010, comparison with the USA. Bull Cancer 2010;97:47-54 (French).
2. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27:3677-83.
3. Plan cancer 2009-2013. 2009. Institut national du cancer, http://www.e-cancer.fr/plancancer-2009-2013.
4. Synthèse de l'activitédes plateformes hospitalières de génétique moléculaire des cancers en 2009. Institut National du Cancer, http://www.e-cancer.fr/soins/plates-formes-hospitalieres- degenetique-moleculaire.
5. Nowak F. Charte des plateformes hospitalières de génétique moléculaire des cancers. Ann Pathol 2011;31:135-7.
6. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-6.
7. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
8. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
9. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697-705.
10. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) Compared With FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:4706-13.
11. Lamy A, Blanchard F, Le Pessot F, et al. Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls. Mod Pathol 2011;24:1090-100.
12. Plesec TP, Hunt JL. KRAS mutation testing in colorectal cancer. Adv Anat Pathol 2009;16:196-203.
13. Perspectives on Emerging Technology (POET). Report: KRAS Mutation Testing in Colorectal Cancer (CRCs). College of American Pathologists: Northfield, IL 2009.
14. Do H, Krypuy M, Mitchell PL, Fox SB, Dobrovic A. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 2008;8:142.
15. van Krieken JH, Jung A, Kirchner T, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 2008;453:417-31.
16. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 2009;27:1130-6.
17. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy- refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010;304:1812-20.
18. Tejpar S, Bokemeyer C, Celik I, Schlichting M, Sartorius E, Van Cutsem. Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 29 (Suppl.): 2011. [abstr 3511].
19. Angulo B, Garcia-Garcia E, Martinez R, et al. A commercial realtime PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J Mol Diagn 2010;12:292-9.
20. Tol J, Dijkstra JR, Vink-Borger ME, et al. High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med 2009;14:2122-31.
21. Weichert W, Schewe C, Lehmann A, et al. KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn 2010;12:35-42.
22. Franklin WA, Haney J, Sugita M, et al. KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. J Mol Diagn 2010;12:43-50.
23. www.biomedicale.parisdescartes.fr/Projet-STIC-MOKAECMPHASE II.
24. Penault-Llorca F. Biomarqueurs en cancérologie: attentes et perspectives. Quelles types de réponses peuvent apporter les centres de ressources biologiques ? Les rencontres de la cancérologie française 2009. 15 et 16 décembre 2008. CitéUniversitaire Internationale de Paris. Paris: France.
25. Lapeyrere N, Mathoulin-pelissier S, Merlio JPI, et al. Prise en charge d'une analyse KRAS: processus et délais KRAS analysis management: process and delays. Ann Pathol 2012;32:81-90.
26. Bonnes pratiques pour la recherche àvisée théranostique de mutations somatiques dans les tumeurs solides. Institut national du cancer. http://www.e-cancer.fr/soins/plates-formes-hospitalieresde- genetique-moleculaire.
27. Bellon E, Ligtenberg MJ, Tejpar S, et al. External quality assessment for KRAS testing is needed: setup of a european program and report of the first joined regional quality assessment rounds. Oncologist 2011;16:467-78.
28. Bibeau F, Frugier H, Crapez E, Lamy PJ, Ychou M, Boissière-Michot F. KRAS mutation testing in patients with metastatic colorectal carcinoma: an 18-month experience emphasizing the risk of falsenegative results. J Clin Oncol 2010;28 (abstr 3572).
29. Selves J, Grand D, Guimbaud R, et al. Impact of the amount of tumor cells in tissue samples for detection of KRAS mutations in colorectal cancer. J Clin Oncol 2010;28:3571 (abstr).
30. Boissière-Michot F, Lopez-Crapez E, Frugier H, et al. KRAS genotyping in rectal adenocarcinomas specimens with low tumor cellularity after neoadjuvant treatment. Modern Pathol 2012;25:731-9.
31. Bibeau F, Frugier H, Denouel A, Sabourin JC, Boissiere-Michot F. Aspect technique de la détermination du statut KRAS dans le cancer colorectal et mise en place en France. Point de vue de l'anatomopathologiste. Bull Cancer 2009;96:S15-22.